Literature DB >> 4045922

Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituent.

T R Jones, A H Calvert, A L Jackman, M A Eakin, M J Smithers, R F Betteridge, D R Newell, A J Hayter, A Stocker, S J Harland.   

Abstract

The synthesis of 12 new 5,8-dideazafolates with isopropyl, cyclopropylmethyl, 2-fluoroethyl, carbamoylmethyl, phenacyl, 3-fluorobenzyl, 5-uracilylmethyl, carboxymethyl, 2-carboxyethyl, 3-cyanopropyl, 3-hydroxypropyl, and cyanomethyl substituents at N10 is described. In general, the synthetic route involved monoalkylation of diethyl N-(4-amino-benzoyl)-L-glutamate, coupling of the resulting secondary amine with 2-amino-6-(bromomethyl)-4-hydroxyquinazoline hydrobromide in N,N-dimethylacetamide with calcium carbonate as the base, and deprotection using mild alkali. The cyanomethyl derivatives was found to be unexpectedly base labile and was therefore prepared by mild acid deprotection of a di-tert-butyl ester. The compounds were tested as inhibitors of purified L1210 thymidylate synthase (TS). Four members of the series were more potent that the N10-hydrogen compound, but none was superior to the previously described N10-propargyl-5,8-dideazafolic acid. Selected compounds were examined as inhibitors of purified L1210 dihydrofolate reductase (DHFR). As desired, N10 substitution in general reduced DHFR inhibitory activity; these results are discussed. As a measure of cytotoxicity, the compounds were examined for their inhibition of the growth of L1210 cells in culture. None of the new substituents conferred enhanced potency relative to N10-propargyl-5,8-dideazafolic acid (ID50 = 5 microM), which, as the best TS inhibitor and a relatively poor DHFR inhibitor, continues to lead this series.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4045922     DOI: 10.1021/jm00148a016

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.

Authors:  Yijun Deng; Xilin Zhou; Sita Kugel Desmoulin; Jianmei Wu; Christina Cherian; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

2.  An analysis of hydrophobic interactions of thymidylate synthase with methotrexate: free energy calculations involving mutant and native structures bound to methotrexate.

Authors:  Ramirededy Nageswara Reddy; Ravichandra Reddy Mutyala; Polamarasetty Aparoy; Pallu Reddanna; Mutyala Rami Reddy
Journal:  J Mol Model       Date:  2009-06-28       Impact factor: 1.810

3.  Escherichia coli thymidylate synthase: amino acid substitutions by suppression of amber nonsense mutations.

Authors:  M L Michaels; C W Kim; D A Matthews; J H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

4.  Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.

Authors:  Lei Wang; Christina Cherian; Sita Kugel Desmoulin; Lisa Polin; Yijun Deng; Jianmei Wu; Zhanjun Hou; Kathryn White; Juiwanna Kushner; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

5.  Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.

Authors:  C Erlichman; B Mitrovski
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.